Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Link Medicine gets $40M to advance neurodegenerative disease therapies
November 2008
SHARING OPTIONS:

CAMBRIDGE, Mass.—Link Medicine Corp., a privately held biotech company focused on neurodegenerative diseases, announced last month it received $40 million of Series C equity financing from biotech investors Clarus Ventures and SV Life Sciences. The funds will be used to help move Link's lead preclinical programs, which seek to develop the first disease-modifying therapies for the treatment of such neurodegenerative diseases as Alzheimer's, Parkinson's, Huntington's and Amyotrophic Lateral Sclerosis (ALS), into human clinical testing. According to Link, the company is pursuing innovative approaches to target a common feature of these disorders—the buildup in nerve cells of incorrectly folded, aggregated and ultimately neurotoxic proteins.

 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.